Lilly Sweet On MacroGenics’ Novel Diabetes Drug Teplizumab
Anti-CD3 monoclonal antibody is now in a pivotal Phase II/III clinical trial for treating underlying disease in type 1 diabetes, Lilly tells “The Pink Sheet” DAILY.
Anti-CD3 monoclonal antibody is now in a pivotal Phase II/III clinical trial for treating underlying disease in type 1 diabetes, Lilly tells “The Pink Sheet” DAILY.